Early allopurinol in asymptomatic hyperuricemia: caution in interpreting modelled cardiorenal benefits
European Journal of Internal Medicine · 2026-11 · 153 · 107166
DOI: 10.1016/j.ejim.2026.107166 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Internal Medicine, 2026-11. Verfasst von Cong Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Imaging and Laboratory Medicine, Jining Medical University, Jining, 272000, Shandong Province, China. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- School of Medical Imaging and Laboratory Medicine, Jining Medical University, Jining, 272000, Shandong Province, China.
- Medical Laboratory Department, Affiliated Hospital of Jining Medical University, Jining, 272029, Shandong Province, China. Electronic address: jincq2008@163.com.
Zitieren
APA
Liu, C., & Jin, C. (2026). Early allopurinol in asymptomatic hyperuricemia: caution in interpreting modelled cardiorenal benefits. European Journal of Internal Medicine, 153, 107166. https://doi.org/10.1016/j.ejim.2026.107166
Vancouver
Liu C, Jin C. Early allopurinol in asymptomatic hyperuricemia: caution in interpreting modelled cardiorenal benefits. European Journal of Internal Medicine. 2026;153:107166. doi:10.1016/j.ejim.2026.107166
BibTeX
@article{Liu2026,
author = {Liu, Cong and Jin, Chengqiang},
title = {Early allopurinol in asymptomatic hyperuricemia: caution in interpreting modelled cardiorenal benefits},
journal = {European Journal of Internal Medicine},
year = {2026},
volume = {153},
pages = {107166},
doi = {10.1016/j.ejim.2026.107166}
}
EUVIMED